课题基金 / 基金详情

基于模块化实时监控平台探究吸入粉雾剂载体对肺部药物递送过程的影响机制

批准号:
82104072
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
张雪娟
依托单位:
学科分类:
药剂学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
张雪娟

项目摘要

结项摘要

张雪娟的其他基金

相似基金

相关文献

中文摘要
吸入粉雾剂具有广阔的市场前景,而高效、低毒吸入粉雾剂研发是亟需攻克的重点领域。载体是吸入粉雾剂递送药物的主体,构建高效递送吸入载体是一种有效策略。但由于缺乏对肺部药物递送过程及影响机理的充分认知,无法精准、高效地指导载体的定向构建,其根本原因在于现有评价体系的局限性。为此,本项目提出构建模块化实时监控平台,实现肺部药物递送过程的分步检测、实时监控及快速解析。前期研究结果证明,此平台可实现肺部递送过程中药物、药物团聚和载体的实时监控,相关结果与肺部药物递送效率具有良好相关性,且可进一步获得具体递送过程,具有用于递送机理研究的巨大潜力。本项目拟构建一系列不同理化性质吸入载体,通过上述平台阐明载体理化性质对肺部药物递送过程的影响机制,并建立载体理化性质与肺部药物递送效率的人工神经网络及定量关系。基于上述定量关系,提出高效递送吸入载体定向构建的理性化策略,为吸入粉雾剂研发提供理论基础与技术支撑。
英文摘要
Dry powder inhalers (DPIs) are known to hold broad market prospects and great application potential. The aerosolization performance enhancement is the pressing need for DPI formulations development. Carriers play a critical role in DPIs since they can facilitate drugs delivery to the lung. Although the construction of efficient carriers has been considered as an effective strategy to improve the aerosolization performance, the absence of awareness on the pulmonary drug delivery processes (PDDPs) and the relevant influence mechanism hinders its precise construction and application. The fundamental reason lies in the limitations of available evaluation approaches of DPIs, which unable to monitor the PDDPs in real-time efficiently and accurately. In view of this, modular process analysis platform (MPAP) is proposed in this project, to realize the divisional detection, real-time monitoring and rapid analysis of PDDPs. Demonstrated by preliminary studies, MPAP could real-time monitor the release of drugs, drug aggregations and carriers in each stage of PDDPs separately, to obtain continuous and specific PDDPs, and thus to be suitable for the investigation of PDDPs mechanism. The presented project schedules to construct a series of carriers with diverse physicochemical properties, and then clarify its influence mechanism on the PDDPs based on MPAP. The artificial neural network and quantitative relation between the physicochemical properties of carriers and aerosolization performance will be established, and thus a more accurate and precise strategy for efficient carrier construction would be obtained. Ultimately, it is expected that this project may provide a new theoretical insight and experimental support for DPIs research and development.
呼吸系统疾病是全球及中国的第5大死因,我国面临巨大的临床用药需求。吸入制剂是呼吸系统疾病的首选疗法,占据了其全球市场份额的84%,已列入我国“十三五”重大新药创制专项,我国潜在市场高达600亿元。吸入粉雾剂因在药物稳定性、肺部药物递送效率和患者顺应性上具有明显优势,已成为吸入制剂的主流品种,具有广阔的市场和开发前景。.开发高效、低毒的吸入粉雾剂是药剂学研发的重点领域。载体是吸入粉雾剂递送药物的主体,通过调控其理化性质,构建高效递送吸入载体是一种有效策略。但由于缺乏对吸入粉雾剂肺部药物递送过程及其影响机理的充分认知,无法精准、高效地指导吸入载体的定向构建及应用。本项目针对吸入粉雾剂肺部药物递送过程及其影响机理不清晰的瓶颈问题,提出构建模块化实时监控平台,实现肺部药物递送过程的分步检测、实时监控及快速解析,以期精准、高效地指导吸入载体的定向构建及应用。基于此,本项目构建了一系列不同理化性质吸入载体,通过上述平台,阐明了载体理化性质对肺部药物递送过程的影响机制,并建立了载体理化性质与肺部药物递送效率的人工神经网络及定量关系。基于这一理论体系,本项目以表面粗糙化载体和表面多孔化载体为模型,成功构建了高效、低毒的硫酸多粘菌素B吸入粉雾剂和西维来司他纳吸入粉雾剂,肺部药物递送效率得到有效改善,并具有良好的体内外安全性。本项目基于载体理化性质对肺部药物递送过程的影响机制,提出了高效递送吸入载体定向构建的理性化策略,攻克了吸入粉雾剂的开发难点,并推广了模块化实时监控平台用于吸入粉雾剂的开发及应用,极大加速了吸入粉雾剂的开发进程。
纳米药物吸入粉雾剂开发的粒径尺度转 换策略及吸入性能调控机制研究
  • 批准号:
    --
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    张雪娟
  • 依托单位:
用于肺部铜绿假单胞菌感染治疗的抗菌吸入粉雾 剂:功能性糖载体的开发及其提高药物在肺部病灶可及性的机制
  • 批准号:
    --
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    张雪娟
  • 依托单位:
国内基金
海外基金